Final Results

Summary by AI BETAClose X

Abingdon Health plc reported final results for the financial year ended 30 June 2025, with total revenue increasing by 40.0% to £8.6 million, driven by strong growth in contract development and manufacturing organisation (CDMO) activities and the acquisition of CS Lifesciences. The company secured several significant contracts, including a US$2 million deal for sexually transmitted disease tests and an £800,000 funding award for malaria diagnostic tests. Despite an adjusted EBITDA loss of £2.7 million for the year, the company's cash position improved to £1.9 million, supported by successful fundraising efforts totaling £5.2 million net of expenses in August 2024 and an additional £3.2 million net of expenses in October 2025 to fund expansion, particularly in the USA. The company anticipates continued revenue growth in FY26.

Disclaimer*

UK 100

Latest directors dealings